Glenmark Pharmaceuticals Receives Zero 483 Observations in U.S. FDA Pre-Approval Inspection at Aurangabad Facility

Glenmark Pharmaceuticals Ltd has announced that the U.S. Food and Drug Administration (U.S. FDA) has completed a Pre-Approval Inspection at the company’s formulations manufacturing facility in Chhatrapati Sambhajinagar (Aurangabad). The inspection was carried out from November 24 to November 28, 2025, and concluded with zero 483 observations. This is a significant update as it indicates a clean inspection report, which is a positive sign for the company's operations and compliance with U.S. FDA standards.